{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:25:00Z","timestamp":1787005500089,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2000,10,1]],"date-time":"2000-10-01T00:00:00Z","timestamp":970358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2000,10,1]],"date-time":"2000-10-01T00:00:00Z","timestamp":970358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2000,10]]},"DOI":"10.1067\/mjd.2000.109071","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T00:17:08Z","timestamp":1027556228000},"page":"S70-S80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":182,"special_numbering":"S","title":["Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis"],"prefix":"10.1067","volume":"43","author":[{"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Fleckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1067\/mjd.2000.109071_bib1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0190-9622(08)81495-8","article-title":"Antifungal agents: an overview. Part I","volume":"30","author":"Gupta","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2000.109071_bib2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0190-9622(94)70112-1","article-title":"Antifungal agents: an overview. Part II","volume":"30","author":"Gupta","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2000.109071_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0733-8635(05)70420-4","article-title":"Current management of onychomycosis","volume":"15","author":"Gupta","year":"1997","journal-title":"Dermatol Clin"},{"issue":"Suppl","key":"10.1067\/mjd.2000.109071_bib4","first-page":"41","article-title":"Biochemical basis for the activity of oral antifungal drugs","volume":"71","author":"Vanden Bossche","year":"1990","journal-title":"Br J Clin Pract"},{"issue":"suppl 39","key":"10.1067\/mjd.2000.109071_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2133.1992.tb00001.x","article-title":"Terbinafine: mode of action and properties of the squalene epoxidase inhibition","volume":"126","author":"Ryder","year":"1992","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2000.109071_bib6","series-title":"Ciclopirox lacquer topical solution 8% package insert","year":"1999"},{"key":"10.1067\/mjd.2000.109071_bib7","first-page":"1","article-title":"Hydroxy-pyridones outstanding biological properties","author":"Markus","year":"1999"},{"key":"10.1067\/mjd.2000.109071_bib8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1439-0507.1997.tb00227.x","article-title":"The hydroxypyridones: a class of antimycotics of its own","volume":"40","author":"Korting","year":"1997","journal-title":"Mycoses"},{"issue":"suppl 1","key":"10.1067\/mjd.2000.109071_bib9","first-page":"97","article-title":"Therapy with ciclopirox lacquer of onychomycosis caused by molds","volume":"37","author":"Ulbricht","year":"1994","journal-title":"Mycoses"},{"key":"10.1067\/mjd.2000.109071_bib10","doi-asserted-by":"crossref","first-page":"506","DOI":"10.2340\/0001555567506510","article-title":"Hendersonula toruloidea infection: successful response of onychomycosis to nail avulsion and topical ciclopirox olamine","volume":"67","author":"Rollman","year":"1987","journal-title":"Acta Derm Venereol"},{"key":"10.1067\/mjd.2000.109071_bib11","first-page":"166","article-title":"A clinical and laboratory study of ciclopirox olamine (8% Batrafen) in the treatment of onychomycosis","volume":"6","author":"Yu","year":"1991","journal-title":"Chin Med Sci J"},{"key":"10.1067\/mjd.2000.109071_bib12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1046\/j.1365-4362.1997.00349.x","article-title":"Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada: a multicenter survey of 2001 patients","volume":"36","author":"Gupta","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1067\/mjd.2000.109071_bib13","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/archderm.1997.03890450124022","article-title":"Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions","volume":"133","author":"Elewski","year":"1997","journal-title":"Arch Dermatol"},{"issue":"suppl 43","key":"10.1067\/mjd.2000.109071_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2133.1994.tb06087.x","article-title":"Onychomycosis is more than a cosmetic problem","volume":"130","author":"Scher","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2000.109071_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0733-8635(05)70420-4","article-title":"Current management of onychomycosis","volume":"15","author":"Gupta","year":"1997","journal-title":"Dermatol Clin"},{"key":"10.1067\/mjd.2000.109071_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.1999.tb00837.x","article-title":"The new oral agents for onychomycosis of the toenails","volume":"13","author":"Gupta","year":"1999","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1067\/mjd.2000.109071_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00002018-200022010-00004","article-title":"An update, with a risk-benefit evaluation of the newer oral antifungal agents to treat onychomycosis","volume":"22","author":"Gupta","year":"2000","journal-title":"Drug Safety"},{"key":"10.1067\/mjd.2000.109071_bib18","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0190-9622(97)70111-7","article-title":"Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial","volume":"37","author":"Drake","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"part 2","key":"10.1067\/mjd.2000.109071_bib19","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0190-9622(98)70490-6","article-title":"Once-weekly fluconazole (150 mg, 300 mg, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail","volume":"38","author":"Scher","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1067\/mjd.2000.109071_bib20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-4362.1996.tb03667.x","article-title":"Double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail","volume":"35","author":"Jones","year":"1996","journal-title":"Int J Dermatol"},{"key":"10.1067\/mjd.2000.109071_bib21","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/S0190-9622(98)70493-1","article-title":"Pharmacokinetics of three doses of once-weekly fluconazole (1250, 300, and 450 mg) in distal subungual onychomycosis of the toenail","volume":"38","author":"Rich","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2000.109071_bib22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2230.1995.tb01353.x","article-title":"Nail incorporation kinetics of terbinafine in onychomycosis patients","volume":"20","author":"Schatz","year":"1995","journal-title":"Clin Exp Dermatol"},{"key":"10.1067\/mjd.2000.109071_bib23","first-page":"6","article-title":"Itraconazole and terbinafine in perspective. From petri dish to patient","author":"De Doncker","year":"1999","journal-title":"Postgrad Med Special Report"},{"key":"10.1067\/mjd.2000.109071_bib24","first-page":"1337","article-title":"Pharmacokinetics and biotransformation of the antimycotic drug ciclopirox olamine in animals and man after topical and systemic administration","volume":"31","author":"Kellner","year":"1981","journal-title":"Arzeimitteschung"},{"key":"10.1067\/mjd.2000.109071_bib25","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1067\/mjd.2000.109072","article-title":"Dermatopharmacology of ciclopirox nail lacquer 8% for the topical treatment of onychomycosis","volume":"43","author":"Bohn","year":"2000","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962200264815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962200264815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T21:24:50Z","timestamp":1759267490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962200264815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,10]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,10]]}},"alternative-id":["S0190962200264815"],"URL":"https:\/\/doi.org\/10.1067\/mjd.2000.109071","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2000,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1067\/mjd.2000.109071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2000 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}